‌

Chromologic LLC SBIR Phase I Award, February 2022

A SBIR Phase I contract was awarded to Chromologic Llc in February, 2022 for $167,470.0 USD from the U.S. Department of Defense and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.

Overview Structured Data Issues Contributors

sbir.gov/node/2237845

Is a

SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient

Chromologic Llc

Government Agency

U.S. Department of Defense

Government Branch

Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense

Award Type

SBIR1

Contract Number (US Government)

W911SR-22-P-00021

Award Phase

Phase I1

Award Amount (USD)

167,4701

Date Awarded

February 14, 2022

End Date

August 13, 2022

Abstract

To meet CBD’s need for a multi-dose formulation of scopolamine hydrobromide trihydrite ChromoLogic proposes to develop a vial add-on containing a self-decontamination cap with a self-healing material to eliminate evaporation and contamination risks through needle punctures in the septum. CL will also perform forced degradation and stability tests with a panel of preservatives to select optimal preservative/concentration and achieve target shelf-life. Overall, CL plans to work with the CBD to ensure this product is an amendment to their already existing FDA process for approval of their single-dose formulation.